Nasdaq stocks posting largest percentage increases
AP - Tue Sep 09, 12:23PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
Is Stemline Therapeutics (STML) Stock a Solid Choice Right Now? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Sep 09, 7:41AM CDT
Stemline Therapeutics is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.
3 Big-Volume Stocks to Trade for Breakouts
at The Street - Tue Sep 09, 6:00AM CDT
These stocks rising on unusual volume are within range of triggering breakout trades.
Stemline Therapeutics to Present at the Aegis Capital 2014 Healthcare & Technology Conference
GlobeNewswire - Mon Sep 08, 6:36AM CDT
Stemline Therapeutics, Inc. (Nasdaq:STML) announced today that Ivan Bergstein, M.D., Stemline's Chief Executive Officer, will present at The Aegis Capital 2014 Healthcare & Technology Conference on Friday, September 12, 2014 at 11:25 AM PT (2:25 PM ET). The conference will be held at the Encore At Wynn Las Vegas in Las Vegas, NV. A live webcast of the presentation can be viewed on the company's website at www.stemline.com.
Stemline Therapeutics to Present at the Rodman & Renshaw 16th Annual Global Investment Conference
GlobeNewswire - Thu Sep 04, 6:00AM CDT
Stemline Therapeutics, Inc. (Nasdaq:STML) announced today that Ivan Bergstein, M.D., Stemline's Chief Executive Officer, will present at the Rodman & Renshaw 16 Annual Global Investment Conference on Tuesday, September 9, 2014 at 11:40 AM ET. The conference will be held at the New York Palace Hotel in New York, NY. A live webcast of the presentation can be viewed on the company's website at www.stemline.com.
Global Hodgkins Lymphoma Therapeutics Market 2014-2018: Bristol Myers Squibb, F. Hoffmann-La Roche, Merck & Co & Pfizer Dominate the Industry
M2 - Fri Aug 22, 9:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/g8ls35/global_hodgkins) has announced the addition of the "Global Hodgkins Lymphoma Therapeutics Market 2014-2018" report to their offering. The Global Hodgkin's Lymphoma Therapeutics market will grow at a CAGR of 6.84 percent over the period 2013-2018. There has been an increase in awareness of Hodgkin's lymphoma among patients and physicians. Enhanced patient and physician awareness is expected to lead to earlier disease diagnosis and treatment. The acceptability of Hodgkin's lymphoma drugs is expected to rise because of the increasing public awareness. Raising general awareness about Hodgkin's lymphoma has led to an increase in research funding and support for clinical and support services. For instance, September 15 is celebrated as WLAD by the LRF. The program was initiated to make people more aware about both Hodgkin's lymphoma and NHL in terms of symptom recognition, early diagnosis, and treatment According to the report the Global Hodgkin's Lymphoma Therapeutics market is driven by several factors. One of the main drivers in this market is the improved diagnostic techniques. Improved diagnostic techniques have led to the treatment of Hodgkin's lymphoma in an aggressive way and have driven revenue growth in a positive direction. Improvement in the diagnosis leads to the early detection and treatment of the disease. Further, the report states that the Global Hodgkin's Lymphoma Therapeutics market is inhibited by some serious challenges. One of the main challenges is the high cost of Hodgkin's lymphoma treatment. Despite the numerous benefits, the high cost of treatment options hinders the acceptability among patients. Many patients do not have the required budget for investing in high-cost treatment options. The Global Hodgkin's Lymphoma Therapeutics market can be divided into eight segments: - Alkylating Antineoplastic Agents - Antibiotic Antineoplastic Agents - Antineoplastics Vinca Alkaloid Agents - Podophyllotoxin Derivative Antineoplastic Agents - Antimetabolite Antineoplastic Agents - Anthracycline Antineoplastic Agents - Antimicrotubular Antineoplastics - Corticosteroids Key Vendors - Bristol Myers Squibb Co. - F. Hoffmann-La Roche Ltd. - Merck & Co. Inc. - Pfizer Inc. Other Prominent Vendors - 4SC AG - Actinium Pharmaceuticals Inc. - Aeterna Zentaris Inc. - Affimed Therapeutics AG - Hospira Inc. - Incyte Corp. - Novartis AG - Philogen S.p.A. - Seattle Genetics Inc. - Sigma-Tau Pharmaceuticals Inc. - Stemline Therapeutics Inc. - Teva Pharmaceutical Industries Ltd. For more information visit http://www.researchandmarkets.com/research/g8...l_hodgkins
Stemline Therapeutics Provides Second Quarter 2014 Financial Results and Corporate Update
GlobeNewswire - Thu Aug 14, 6:00AM CDT
Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical stage biopharmaceutical company developing novel drugs targeting cancer stem cells (CSCs) and tumor bulk, today provided a corporate update and reported financial results for the quarter ended June 30, 2014.
Stemline Therapeutics to Present at the Wedbush Life Sciences Management Access Conference
GlobeNewswire - Tue Aug 05, 6:00AM CDT
Stemline Therapeutics, Inc. (Nasdaq:STML) announced today that Ivan Bergstein, M.D., Stemline's Chief Executive Officer, will present at the 2014 Wedbush Life Sciences Management Access Conference on Tuesday, August 12, 2014 at 3:05 PM ET. The conference will be held at the Le Parker Meridien in New York, NY. A live webcast of the presentation can be viewed on the Company's website at www.stemline.com.
Stemline Therapeutics Announces Opening of SL-401 Corporate IND and Start of Clinical Trials in BPDCN and AML
GlobeNewswire - Mon Jul 28, 5:01AM CDT
Stemline Therapeutics, Inc. (Nasdaq:STML) announced today the opening of its SL-401 Investigational New Drug (IND) and initiation of a broad clinical development program including trials in blastic plasmacytoid dendritic cell neoplasm (BPDCN) and acute myeloid leukemia (AML). SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) present on cancer stem cells (CSCs) and tumor bulk of many hematologic cancers. SL-401 has completed a physician-sponsored Phase 1/2 trial and demonstrated a tolerable safety profile and clinical activity in multiple indications, including durable complete responses (CRs), in BPDCN and relapsed/refractory AML. Seven of nine evaluable BPDCN patients had objective responses, including 5 CRs. Stemline has now initiated a corporate-sponsored multicenter, open-label trial in patients with BPDCN and relapsed/refractory AML. This study is designed to accrue at least 60 patients, including a brief lead-in that transitions into a larger expansion stage in these indications. Additional trials in other IL-3R expressing malignancies will follow this year and into early next year.
Stemline (STML) Enters Oversold Territory - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jul 18, 10:01AM CDT
Stemline (STML) Enters Oversold Territory
Malignant Glioma - Pipeline Review, H1 2014
M2 - Thu Jul 03, 5:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ljjnrf/malignant_glioma) has announced the addition of the "Malignant Glioma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Malignant Glioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malignant Glioma and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Malignant Glioma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Malignant Glioma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Sanofi - ZIOPHARM Oncology, Inc. - Cytomedix, Inc. - Stemline Therapeutics, Inc. - EirGen Pharma Ltd. For more information visit http://www.researchandmarkets.com/research/lj...ant_glioma
High-Grade Glioma - Pipeline Review, H1 2014
M2 - Fri Jun 27, 5:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pmhvrt/highgrade_glioma) has announced the addition of the "High-Grade Glioma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for High-Grade Glioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for High-Grade Glioma and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for High-Grade Glioma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding High-Grade Glioma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Boehringer Ingelheim GmbH - GlaxoSmithKline plc - Genentech, Inc. - Bayer AG - Virttu Biologics Limited - AngioChem Inc. - Stemline Therapeutics, Inc. - TAU Therapeutics, LLC - Tocagen Inc. - AROG Pharmaceuticals LLC For more information visit http://www.researchandmarkets.com/research/pm...ade_glioma
Medulloblastoma - Pipeline Review, H1 2014
M2 - Wed Jun 25, 3:42AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ld2gzs/medulloblastoma) has announced the addition of the "Medulloblastoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Medulloblastoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Medulloblastoma and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Medulloblastoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Medulloblastoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Medulloblastoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects Companies Mentioned: - Archer Biosciences - Conkwest - Lixte Biotechnology Holdings - Novartis - Stemline Therapeutics - Takeda Pharmaceutical - TheraBiologics - ThromboGenics For more information visit http://www.researchandmarkets.com/research/ld...loblastoma
Stemline Therapeutics Announces Presentation of SL-501 Preclinical Efficacy Data in TKI-Resistant CML at the Annual Meeting of the American Association of Cancer Research (AACR)
GlobeNewswire - Tue Apr 01, 6:03AM CDT
Stemline Therapeutics, Inc. (Nasdaq:STML) announced today that data demonstrating SL-501 inhibits the growth of tyrosine kinase inhibitor (TKI) resistant chronic myeloid leukemia (CML) cells in preclinical models was selected for poster presentation at the Annual Meeting of the American Association for Cancer Research (AACR) Conference, being held April 5-9, 2014 in San Diego, CA. SL-501 is a highly potent targeted therapy directed to the interleukin-3 receptor (IL-3R). SL-501 is a next generation variant of SL-401; SL-401 is currently being advanced in clinical trials of multiple hematologic cancers.
Where are They Now? Biotech IPO Class of 2013, March Edition
Cory Renauer, The Motley Fool - Motley Fool - Wed Mar 26, 5:30PM CDT
This year you can't squeeze a pipette without hitting another biotech offering. The red-hot sector has seen more than 25 IPOs so far this year. Many are doubling and tripling in price in their first days of trading. In a frenzied market like this...
Stemline Therapeutics to Present at the 26th Annual ROTH Conference
GlobeNewswire - Thu Mar 06, 6:09AM CST
Stemline Therapeutics, Inc. (Nasdaq:STML) announced today that Ivan Bergstein, M.D., Stemline's CEO, will present at the 26th Annual ROTH Conference on Tuesday, March 11, 2014 at 2:30 PM PT. The conference will be held at the Ritz-Carlton, Laguna Niguel in Dana Point, CA. A live webcast of the presentation can be viewed on the Company's website at www.stemline.com.
Stemline Therapeutics to Present at Cowen and Company Health Care Conference
GlobeNewswire - Wed Feb 26, 6:00AM CST
Stemline Therapeutics, Inc. (Nasdaq:STML) announced today that Ivan Bergstein, M.D., Stemline's CEO, will present at the Cowen and Company 34th Annual Health Care Conference on Tuesday, March 4, 2014 at 9:20 AM ET. The conference will be held at the Boston Marriott Copley Place in Boston, MA.
Stemline Therapeutics (STML) Worth Watching: Stock Rises 8.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Feb 24, 8:25AM CST
Stemline Therapeutics was a big mover last session, with shares rising over 8%.
5 Stocks Breaking Out on Unusual Volume
at The Street - Mon Feb 24, 8:11AM CST
These stocks trading with big volume are within range of triggering breakout trades.